George Clinical scientific leaders and staff members enjoyed significant involvement in the 2021 American Society of Nephrology’s Kidney Week including contributions to abstracts, poster sessions, publications and presentations. Considering the organization’s deep history in kidney and metabolic clinical research, it is unsurprising yet inspiring to see such a broad set of renal research continuing despite the challenge posed by a global pandemic.
“The kidney community is deeply committed to continuing education, learning more about the latest scientific advances, and improving care for the millions of people with kidney diseases,” said Susan E. Quaggin, MD, ASN president.
Scientific leaders Vivekanand Jha, MD and Hiddo Jan L Heerspink, PhD authored posters, oral abstracts and speak on panels of global interest. Demonstrating the depth and breadth of ongoing renal research Professor Jha’s contributions include:
- An ISN-DOPPS Survey of the Global Impact of the COVID-19 Pandemic on In-Centre Haemodialysis Services;
- COVID-19 Pandemic Highlights Global Inequities in Chronic Hemodialysis Care: A DOPPS/ISN Survey;
- An ISN-DOPPS Survey of the Global Impact of COVID-19 Pandemic on Home Peritoneal Dialysis Services;
- Identifying Factors Associated with Clinically Adjudicated Drug-Induced AKI in Children;
- Effects of Daprodustat on Hemoglobin and Quality of Life in Patients with CKD: Results of the ASCEND-NHQ Randomized, Double-Blind, Placebo-Controlled for which George Clinical provided scientific leadership and project operations as well as speaking on the Worldwide Perspective on Ethics of Dialysis Allocation Heightened by COVID-19.
Professor Heerspink’s widespread renal work is also on full display featuring:
- Randomized Clinical Study to Evaluate the Effect of Personalized Therapy on Patients with Immunoglobulin A Nephropathy (IgAN)
- Estimating Long-Term Survival Rates in Patients with Anaemia of Non-Dialysis-Dependent CKD: An Expert Elicitation
- DAPA-CKD: A Regional Analysis of Kidney and Cardiovascular Outcomes
- Effects of Dapagliflozin in Patients with CKD and Albuminuria, with and Without Diabetes, by Use and Non-Use of Cardiovascular Medications: DAPA-CKD Trial
- Correlates and Consequences of an Acute Decline in Estimated Glomerular Filtration Rate in Response to the SGLT-2 Inhibitor Dapagliflozin
- Effect of Finerenone In Non-Diabetic CKD: Design of the FIND-CKD Trial In Non-Diabetic CKD: Design of the FIND-CKD Trial;
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients With IgA Nephropathy: The ALIGN Study;
- The Effect of Dapagliflozin on Rate of Kidney Function Decline in Patients with CKD: A Prespecified Analysis from the DAPA-CKD Trial; and speaking live on Biomarkers That Can Be Used to Evaluate the Effectiveness of New Renoprotective Drugs.
“This impressive collection of studies represent not only the vanguard of renal clinical research but also meaningful progress in the field that will positively impact patient care and subsequent research for years to come,” said Chief Medical Officer Maria Ali.
In addition, the work of several other George Clinical scientific leaders participating also deserves attention comprising:
- Targeted Alteplase Administration to Improve Hemodialysis Catheter Patency: A Quality Improvement Pilot Study
- The Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Initiation in Adults with Atrial Fibrillation (AF) by eGFR Category
- Leveraging High-Content Imaging Platforms for Drug Discovery
- The Comparative Effectiveness and Safety of Direct Oral Anticoagulant (DOAC) and Warfarin Initiation in Adults with Atrial Fibrillation (AF) by eGFR Category
- Kidney Disease in the Aftermath of COVID-19 Infection
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients With IgA Nephropathy: The ALIGN Study for which George Clinical provides scientific leadership
- Serum and Glomerular Complement Components as Biomarkers in the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort (GRACE-IgANI)
- Natural History of Focal Segmental Glomerulosclerosis (FSGS): The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
- Proteinuria End Points and Associations with Renal Survival in FSGS: Analysis of the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
- Natural History of IgA Nephropathy: Analysis of a UK National RaDaR IgA Nephropathy Cohort
- International IgA Nephropathy Network (IIgANN) Risk Prediction and Longitudinal Outcomes in the First South-Asian Prospective IgA Nephropathy Cohort (GRACE-IgANI)
- Reduction of Urinary Levels of Lectin Pathway Complement Components in an IgA Vasculitis Patient After MASP-2 Inhibition with Narsoplimab
- An International Delphi Survey on IgA Nephropathy: Results from the DEFINE Physicians Study
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients With IgA Nephropathy: The ALIGN Study
- An ISN-DOPPS Survey of the Global Impact of the COVID-19 Pandemic on In-Centre Hemodialysis Services
- COVID-19 Pandemic Highlights Global Inequities in Chronic Hemodialysis Care: A DOPPS/ISN Survey
- An ISN-DOPPS Survey of the Global Impact of COVID-19 Pandemic on Home Peritoneal Dialysis Services
- An ISN-DOPPS Survey of the Global Impact of the COVID-19 Pandemic on In-Centre Haemodialysis Services
- COVID-19 Pandemic Highlights Global Inequities in Chronic Hemodialysis Care: A DOPPS/ISN Survey
- An ISN-DOPPS Survey of the Global Impact of COVID-19 Pandemic on Home Peritoneal Dialysis Services
- Estimating Long-Term Survival Rates in Patients with Anemia of Non-Dialysis-Dependent CKD: An Expert Elicitation
- Characterization of Gout in US Patients Treated with Hemodialysis (HD) and Peritoneal Dialysis (PD)
- Clinical Research Offers Potential Benefit to Patients and No Obvious Harm to Clinical Value
- Conservative Kidney Management Practice Patterns in the United States: A CKDopps Analysis
- Associations Between Serum Biomarkers of Iron Stores and the Progression to Kidney Failure in Patients with Moderate-to-Severe CKD
- International Variation in the Incidence of Kidney Failure in the CKD Outcomes and Practice Patterns Study (CKDopps)
- Estimating Long-Term Survival Rates in Patients with Anemia of Non-Dialysis-Dependent CKD: An Expert Elicitation
- Increasing Bone Mineral Density Is Associated with Vascular Calcification in Children and Young Adults with CKD Stages 4-5 and on Dialysis
- Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE where George Clinical global scientific leadership, steering committee management, endpoint adjudication, operations team were involved
- Atrasentan in Patients With Proteinuric Glomerular Diseases: The AFFINITY Study
- The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study which assessed the effects and safety of oral methylprednisolone on significant kidney outcomes for patients with IgAN.
Contact our business development team to learn more about how our international teams enable global kidney and metabolic studies from early phase research all the way through post-market pharmacovigilance as well as the Global Kidney Patient Trial Network (GKPTN).
